Cargando…
A Consensus Statement on acromegaly therapeutic outcomes
The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management of acromegaly were last published in 2014; since then, new pharmacological agents have been developed and...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136157/ https://www.ncbi.nlm.nih.gov/pubmed/30050156 http://dx.doi.org/10.1038/s41574-018-0058-5 |
_version_ | 1783518188730843136 |
---|---|
author | Melmed, Shlomo Bronstein, Marcello D. Chanson, Philippe Klibanski, Anne Casanueva, Felipe F. Wass, John A. H. Strasburger, Christian J. Luger, Anton Clemmons, David R. Giustina, Andrea |
author_facet | Melmed, Shlomo Bronstein, Marcello D. Chanson, Philippe Klibanski, Anne Casanueva, Felipe F. Wass, John A. H. Strasburger, Christian J. Luger, Anton Clemmons, David R. Giustina, Andrea |
author_sort | Melmed, Shlomo |
collection | PubMed |
description | The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management of acromegaly were last published in 2014; since then, new pharmacological agents have been developed and new approaches to treatment sequencing have been considered. Thirty-seven experts in the management of patients with acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and clinical opinion. They considered current treatment outcome goals with a focus on the impact of current and emerging somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists on biochemical, clinical, tumour mass and surgical outcomes. The participants discussed factors that would determine pharmacological choices as well as the proposed place of each agent in the guidelines. We present consensus recommendations highlighting how acromegaly management could be optimized in clinical practice. |
format | Online Article Text |
id | pubmed-7136157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-71361572020-04-08 A Consensus Statement on acromegaly therapeutic outcomes Melmed, Shlomo Bronstein, Marcello D. Chanson, Philippe Klibanski, Anne Casanueva, Felipe F. Wass, John A. H. Strasburger, Christian J. Luger, Anton Clemmons, David R. Giustina, Andrea Nat Rev Endocrinol Consensus Statement The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management of acromegaly were last published in 2014; since then, new pharmacological agents have been developed and new approaches to treatment sequencing have been considered. Thirty-seven experts in the management of patients with acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and clinical opinion. They considered current treatment outcome goals with a focus on the impact of current and emerging somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists on biochemical, clinical, tumour mass and surgical outcomes. The participants discussed factors that would determine pharmacological choices as well as the proposed place of each agent in the guidelines. We present consensus recommendations highlighting how acromegaly management could be optimized in clinical practice. Nature Publishing Group UK 2018-07-26 2018 /pmc/articles/PMC7136157/ /pubmed/30050156 http://dx.doi.org/10.1038/s41574-018-0058-5 Text en © Springer Nature Limited 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Consensus Statement Melmed, Shlomo Bronstein, Marcello D. Chanson, Philippe Klibanski, Anne Casanueva, Felipe F. Wass, John A. H. Strasburger, Christian J. Luger, Anton Clemmons, David R. Giustina, Andrea A Consensus Statement on acromegaly therapeutic outcomes |
title | A Consensus Statement on acromegaly therapeutic outcomes |
title_full | A Consensus Statement on acromegaly therapeutic outcomes |
title_fullStr | A Consensus Statement on acromegaly therapeutic outcomes |
title_full_unstemmed | A Consensus Statement on acromegaly therapeutic outcomes |
title_short | A Consensus Statement on acromegaly therapeutic outcomes |
title_sort | consensus statement on acromegaly therapeutic outcomes |
topic | Consensus Statement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136157/ https://www.ncbi.nlm.nih.gov/pubmed/30050156 http://dx.doi.org/10.1038/s41574-018-0058-5 |
work_keys_str_mv | AT melmedshlomo aconsensusstatementonacromegalytherapeuticoutcomes AT bronsteinmarcellod aconsensusstatementonacromegalytherapeuticoutcomes AT chansonphilippe aconsensusstatementonacromegalytherapeuticoutcomes AT klibanskianne aconsensusstatementonacromegalytherapeuticoutcomes AT casanuevafelipef aconsensusstatementonacromegalytherapeuticoutcomes AT wassjohnah aconsensusstatementonacromegalytherapeuticoutcomes AT strasburgerchristianj aconsensusstatementonacromegalytherapeuticoutcomes AT lugeranton aconsensusstatementonacromegalytherapeuticoutcomes AT clemmonsdavidr aconsensusstatementonacromegalytherapeuticoutcomes AT giustinaandrea aconsensusstatementonacromegalytherapeuticoutcomes AT melmedshlomo consensusstatementonacromegalytherapeuticoutcomes AT bronsteinmarcellod consensusstatementonacromegalytherapeuticoutcomes AT chansonphilippe consensusstatementonacromegalytherapeuticoutcomes AT klibanskianne consensusstatementonacromegalytherapeuticoutcomes AT casanuevafelipef consensusstatementonacromegalytherapeuticoutcomes AT wassjohnah consensusstatementonacromegalytherapeuticoutcomes AT strasburgerchristianj consensusstatementonacromegalytherapeuticoutcomes AT lugeranton consensusstatementonacromegalytherapeuticoutcomes AT clemmonsdavidr consensusstatementonacromegalytherapeuticoutcomes AT giustinaandrea consensusstatementonacromegalytherapeuticoutcomes |